| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(13 years from now) | |
Zoryve is owned by Arcutis.
Zoryve contains Roflumilast.
Zoryve has a total of 4 drug patents out of which 0 drug patents have expired.
Zoryve was authorised for market use on 29 July, 2022.
Zoryve is available in cream;topical dosage forms.
Zoryve can be used as topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1).
The generics of Zoryve are possible to be released after 25 August, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 29, 2025 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 29 July, 2022
Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)
Dosage: CREAM;TOPICAL
ZORYVE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic